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Background
According to the American Psychiatric Association
practice guidelines, if a patient with Major Depressive
Disorder (MDD) has not responded or achieved only a
partial response after 4-8 weeks of therapy, a dose
change, switch to a new drug, or augmentation therapy
is recommended [1].
Combined use of standard antidepressants with dopami-
nergic agents and psychostimulants can lead to accelerate
and enhance response if administered early in the course
of treatment [2].
Materials and methods
Using a sample of 100 patients with diagnosis of MDD
who have been visited in Barcelona’s Sant Martí Sud
outpatient mental health center during the year 2008,
Sociodemographical (gender, age) and clinical data (pre-
sent toxic consume, presence of psychiatric background,
use of antipsychotics) are analysed with SPSS 15.0 statis-
tical package.
Results
Methylphenidate is used in 3% of the sample with an
average dose of 20 mg/d. There is a predominancy in
the female gender (66.7%), a global average age 66.33 ±
7 years. The psychiatric background most frequently
found is the presence of previous depressive disorder
episodes (66.7%). None of these patients had toxic abuse
nor had been hospitalised.
Conclusions
The use of metilphedinate is still not frequent in our
sample as augmentation strategy of the antidepressive
treatment. However initial results show that the combi-
nation with metilphenidate can be useful for patients in
need of a rapid improvement in depression, particularly
in those with chronic treatment-resistant depression but
the tolerability of the combination may limit its use [2].
Further investigation using different treatment to
achieve remission in patients with major depression is
necessary.
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